Eupraxia Pharmaceuticals Inc. sold 7,607,145 common shares at US$7.00 each, plus pre-funded warrants for 1,428,571 shares. The material change date is February 20, 2026.
Latest Eupraxia Pharmaceuticals news
We have not published a story on Eupraxia Pharmaceuticals yet. When there is news, it will appear here.
Latest balance sheet, Dec 31, 2025 (40-F): cash and equivalents $80.6 million.
Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.
Questions about Eupraxia Pharmaceuticals
Has Eupraxia Pharmaceuticals raised money recently?
Our latest story on this, dated Mar 6, 2026: "Eupraxia Pharmaceuticals reports closing of US$63.2 million public offering". The story links the filing or release it is based on. Read the story.
What is the ticker symbol of Eupraxia Pharmaceuticals?
Eupraxia Pharmaceuticals, Inc. trades under the ticker EPRX on TSX.
Where is Eupraxia Pharmaceuticals listed?
Eupraxia Pharmaceuticals, Inc. is listed on TSX. Our directory also records these other listings: LS:A3EGRS; LSX:A3EGRS; NASDAQ:EPRX; NEO:EPRX.
What is the SEC CIK of Eupraxia Pharmaceuticals?
The SEC Central Index Key (CIK) for Eupraxia Pharmaceuticals, Inc. is 1581178. Its filings are on SEC EDGAR.
Which country or territory is Eupraxia Pharmaceuticals listed under?
Our directory records Eupraxia Pharmaceuticals, Inc. under Canada.
What does Eupraxia Pharmaceuticals do?
Our directory classifies Eupraxia Pharmaceuticals, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
What is the ISIN of Eupraxia Pharmaceuticals?
The ISIN recorded for Eupraxia Pharmaceuticals, Inc. is CA29842P1053.
Does aibio.space cover Eupraxia Pharmaceuticals?
aibio.space lists Eupraxia Pharmaceuticals, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
Where is Eupraxia Pharmaceuticals incorporated?
SEC records list its state or country of incorporation as A1.
What was Eupraxia Pharmaceuticals's revenue last year?
$0 for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Is Eupraxia Pharmaceuticals profitable?
Eupraxia Pharmaceuticals, Inc. reported a net loss of $38.6 million for the fiscal year ended Dec 31, 2025, and used $28.6 million of cash in operations, per its annual report to the SEC.
How much does Eupraxia Pharmaceuticals spend on research and development?
$21.3 million in the fiscal year ended Dec 31, 2025, per its annual report.
How much cash does Eupraxia Pharmaceuticals have?
$80.6 million in cash at Dec 31, 2025, per its 40-F.
What is the latest Eupraxia Pharmaceuticals (EPRX) stock news?
Our latest story on Eupraxia Pharmaceuticals, dated Mar 6, 2026: "Eupraxia Pharmaceuticals reports closing of US$63.2 million public offering". Eupraxia Pharmaceuticals Inc. sold 7,607,145 common shares at US$7.00 each, plus pre-funded warrants for 1,428,571 shares. The material change date is February 20, 2026. Source.
Is Eupraxia Pharmaceuticals a smaller reporting company?
SEC records list Eupraxia Pharmaceuticals, Inc.'s filer category as: <br>Emerging growth company.
Investor discussion: Eupraxia Pharmaceuticals
Members talk about Eupraxia Pharmaceuticals (EPRX). Reader posts, not aibio.space reporting, and not investment advice.
Rules
Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
Say whether you hold the stock. Every post states long, short or no position.
No paid or sponsored posts. Do not post for anyone who pays or rewards you.
No buy or sell calls and no price targets.
No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
No personal details and no spam. No links at all for your first 7 days as a member.
Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.
Capital-markets timeline
Financings, listing notices, splits, legal actions and other investor events at Eupraxia Pharmaceuticals, newest first. Each line links the filing it comes from.
Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open TSX:EPRX on TradingView.
SEC filings and registration
SEC name
Eupraxia Pharmaceuticals Inc.
CIK
1581178
Industry (SIC)
Pharmaceutical Preparations (2834)
US tickers
EPRX (Nasdaq)
State or country of incorporation
A1
Fiscal year ends
December 31
Filer category
<br>Emerging growth company
Business address
2198 YUKON STREET, VANCOUVER, V5Y 3P1
Phone
250-590-3968
Recent filings (8-K and 6-K are the company's own announcements)
Source: SEC EDGAR, retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.
Listing details
Eupraxia Pharmaceuticals, Inc. is a public biotech or pharmaceutical company listed on TSX under the ticker EPRX, recorded under Canada. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.
Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.
Published and maintained by aibio.space. Not investment advice. How we work.
Who manages this pageThis page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio